Calcium channel blockers and pain therapy.
This review focuses on the advances in the development of N-type calcium channel blockers as analgesic agents over the last 2 years. Firstly, it highlights the clinical progress with SNX-111 (Ziconotide; Elan Pharmaceuticals, Smithfield, RI) and then secondly, it outlines the various approaches being taken by researchers to design orally active, selective, small molecule modulators without the perceived disadvantages associated with SNX-111.
Cox
B
B
Glaxo Wellcome Research and Development, Department of Medicinal Chemistry 1, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom. BC5958@glaxowellcome.co.uk
D000818:Animals; D002121:Calcium Channel Blockers / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D010146:Pain / Q000188:drug therapy*
D002121:Calcium Channel Blockers